This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
L.B. Foster (FSTR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
L.B. Foster (FSTR) delivered earnings and revenue surprises of 73.68% and 1.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Nutrien (NTR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Weaker fertilizer prices and higher natural gas costs are expected to have affected Nutrien's (NTR) Q1 performance.
Here is What to Know Beyond Why Nutrien Ltd. (NTR) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Nutrien (NTR). This makes it worthwhile to examine what the stock has in store.
Earnings Preview: Nutrien (NTR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Nutrien (NTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scotts Miracle-Gro (SMG) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Scotts (SMG) delivered earnings and revenue surprises of 18.13% and 5.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Nutrien (NTR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Nutrien (NTR) closed at $69, marking a -0.1% move from the previous day.
Nutrien (NTR) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Nutrien (NTR) closed the most recent trading day at $71.23, moving +0.86% from the previous trading session.
Is Trending Stock Nutrien Ltd. (NTR) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Nutrien (NTR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Nutrien (NTR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Nutrien (NTR) closed at $73.91 in the latest trading session, marking a -1.3% move from the prior day.
Nutrien (NTR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Nutrien (NTR) closed the most recent trading day at $72.21, moving -1.49% from the previous trading session.
Nutrien (NTR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Nutrien (NTR) closed at $73.04, marking a -1.48% move from the previous day.
Nutrien (NTR) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Nutrien (NTR) closed the most recent trading day at $72.71, moving +0.78% from the previous trading session.
Nutrien (NTR) Stock Moves -1.13%: What You Should Know
by Zacks Equity Research
Nutrien (NTR) closed the most recent trading day at $74.37, moving -1.13% from the previous trading session.
Brokers Suggest Investing in Nutrien (NTR): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Nutrien (NTR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Nutrien (NTR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Nutrien (NTR) closed at $72.68 in the latest trading session, marking a -0.41% move from the prior day.
Nutrien (NTR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Nutrien (NTR) closed at $79.59, marking a -1.95% move from the previous day.
CF Industries (CF) & Lotte Chemical Ink MoU for Ammonia Project
by Zacks Equity Research
The MOU will allow CF Industries (CF) and Lotte Chemical to evaluate the joint development of and investment in a greenfield clean ammonia production facility in the United States.
Wall Street Bulls Look Optimistic About Nutrien (NTR): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Nutrien (NTR) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Nutrien's (NTR) Earnings and Revenues Miss Estimates in Q4
by Zacks Equity Research
Market volatility, supply-chain disruptions & lower sales volume weighs on the fourth-quarter performance of Nutrien (NTR).
Nutrien (NTR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Nutrien (NTR) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Nutrien (NTR) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nutrien (NTR) delivered earnings and revenue surprises of -23.19% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Nutrien (NTR) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Nutrien (NTR) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Copa Airlines and Nutrien have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Copa Airlines and Nutrien are part of the Zacks Bull and Bear of the Day article.
Nutrien (NTR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Strong demand for potash and phosphate is expected to have driven Nutrien's (NTR) performance in Q4 amid headwinds from elevated natural gas costs.
Bear of the Day: Nutrien Limited (NTR)
by Andrew Rocco
Canada-based fertilizer firm Nutrien is seeing slower growth, poor price action, and potentially higher input costs. Andrew Rocco explains why investors should be cautious for now.